In medical science the whole-brain radiotherapy or WBRT is considered to be life saving tool with immense therapeutic advantages, especially in case of adults. However, there could be far-reaching adverse consequences of using the WBRT process in the long run. Now a study conducted by Nell Hodgson Woodruff School of Nursing together with the Winship Cancer Institute highlights the positive results of using cognitive drug named Memantine.
The research team with Deborah Watkins-Bruner, a professor, selected as many as 508 eligible adults undergoing WBRT. All these people were diagnosed for brain cancer. Randomly selected patients received placebo or Meamantine within a time span of three days of initial WBRT. They also received these doses for 24 weeks in varying doses, small initially, and larger gradually.
After a series of intensive experiments Watkins Bruner came out with the following statement. “We were pleased that the preliminary results showed better cognitive function over time in those who took Memantine.” Results were positive and there was much delay in the time span for cognitive decline in such people.
No comments:
Post a Comment